MedTrace Logo

A Study of the Safety of REN001 in Patients With McArdle Disease

NCT04226274 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-01-12

No results posted yet for this study

Summary

The purpose of this study is to assess REN001 safety in subjects with McArdle Disease

Conditions

  • McArdle Disease

Interventions

DRUG

REN001

Once daily for 12 weeks

Sponsors & Collaborators

  • Reneo Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Rosaline Quinlivan, MD · MRC Centre for Neuromuscular Diseases, London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2021-10-11
Completion
2021-10-11

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226274 on ClinicalTrials.gov